Literature DB >> 15001389

Specificity of the MAP kinase ERK2 for phosphorylation of tyrosine hydroxylase.

Montserrat Royo1, S Colette Daubner, Paul F Fitzpatrick.   

Abstract

Short-term regulation of catecholamine biosynthesis involves reversible phosphorylation of several serine residues in the N-terminal regulatory domain of tyrosine hydroxylase. The MAP kinases ERK1/2 have been identified as responsible for phosphorylation of Ser31. As an initial step in elucidating the effects of phosphorylation of Ser31 on the structure and activity of tyrosine hydroxylase, the kinetics of phosphorylation of the rat enzyme by recombinant rat ERK2 have been characterized. Complete phosphorylation results in incorporation of 2mol of phosphate into each subunit of tyrosine hydroxylase. The S8A and S31A enzymes only incorporate a single phosphate, while the S19A and S40A enzymes incorporate two. Phosphorylation of S8A tyrosine hydroxylase is nine times as rapid as phosphorylation of the S31A enzyme, consistent with a ninefold preference of ERK2 for Ser31 over Ser8.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001389     DOI: 10.1016/j.abb.2003.12.027

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  3 in total

1.  Kinetics of regulatory serine variants of tyrosine hydroxylase with cyclic AMP-dependent protein kinase and extracellular signal-regulated protein kinase 2.

Authors:  Montserrat Royo; S Colette Daubner
Journal:  Biochim Biophys Acta       Date:  2006-02-14

2.  Identification of tyrosine hydroxylase as a physiological substrate for Cdk5.

Authors:  Janice W Kansy; S Colette Daubner; Akinori Nishi; Naoki Sotogaku; Michael D Lloyd; Chan Nguyen; Lin Lu; John W Haycock; Bruce T Hope; Paul F Fitzpatrick; James A Bibb
Journal:  J Neurochem       Date:  2004-10       Impact factor: 5.372

3.  Effects of phosphorylation by protein kinase A on binding of catecholamines to the human tyrosine hydroxylase isoforms.

Authors:  Giri R Sura; S Colette Daubner; Paul F Fitzpatrick
Journal:  J Neurochem       Date:  2004-08       Impact factor: 5.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.